Circulating transforming growth factor beta 1 (TGF-beta 1) in Guillain-Barre syndrome: decreased concentrations in the early course and increase with motor function
| Autor: | Jean-Claude Raphaël, Laurent Bélec, Alain Créange, Romain K. Gherardi, Bernard Clair, Jean-Denis Degos |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
medicine.medical_specialty
Time Factors Hydrocortisone medicine.medical_treatment Plasma Cells Polyradiculoneuropathy Inflammation Severity of Illness Index Proinflammatory cytokine Pathogenesis Adjuvants Immunologic Cell Movement Transforming Growth Factor beta Internal medicine medicine Humans alpha-Macroglobulins Prospective Studies Plasma Exchange Guillain-Barre syndrome biology business.industry Immunoglobulins Intravenous Transforming growth factor beta Transforming Growth Factor alpha medicine.disease Editorial Commentary Psychiatry and Mental health Endocrinology Cytokine Papers Disease Progression biology.protein Surgery Neurology (clinical) Psychomotor Disorders medicine.symptom Psychomotor disorder business medicine.drug |
| Zdroj: | Journal of Neurology, Neurosurgery & Psychiatry. 64:162-165 |
| ISSN: | 0022-3050 |
| DOI: | 10.1136/jnnp.64.2.162 |
| Popis: | OBJECTIVE To delineate the possible implication of the immunosuppressive cytokine transforming growth factor beta 1 (TGF-β1) in the pathogenesis of Guillain-Barre syndrome. Guillain-Barre syndrome is a disorder that may implicate cytokines in its pathogenesis. TGF-β1 is a potent anti-inflammatory cytokine occasionally shown to be regulated in the course of demyelinating disorders. METHODS The study measured circulating proinflammatory and anti-inflammatory cytokines from the progressing phase to early recovery in patients with Guillain-Barre syndrome. Plasma concentrations of TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-10, and TGF-β1 were prospectively evaluated in 15 patients with Guillain-Barre syndrome every three days for the first 15 days after admission to hospital, and in 15 controls with non-inflammatory neurological diseases. RESULTS Concentrations of TGF-β1 in plasma were decreased in 13/15 patients (87 %) at day 1, remained low during progression and the plateau of paralysis (days 1–10), and then progressively increased up to control concentrations during early recovery (days 12–15). Concentrations of plasma TGF-β1 correlated positively with motor function, the lowest values being found in the most disabled patients. Concentrations of plasma TGF-β1 were decreased before any treatment, and during treatment by either plasma exchange or intravenous immunoglobulins, plasma exchange being associated with a more pronounced decrease in TGF-β1 at day 7. Circulating TNF-α concentrations were raised, as previously reported, when other cytokines were either randomly increased (IL-2, IL-6), or undetectable (IL-1, IL-4, IL-7, IL-10). CONCLUSIONS Down regulation of TGF-β1 in the early course of Guillain-Barre syndrome could participate in neural inflammation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|